Computational Approach Reveals Pronociceptive Potential of Cannabidiol in Osteoarthritis: Role of Transient Receptor Potential Channels

Systems pharmacology employs computational and mathematical methods to study the network of interactions a drug may have within complex biological pathways. These tools are well suited for research on multitarget drugs, such as natural compounds, in diseases with complex etiologies, such as osteoarthritis (OA). The present study focuses on cannabidiol (CBD), a non-psychoactive constituent of cannabis, targeting over 60 distinct molecular targets as a potential treatment for OA, a degenerative joint disease leading to chronic pain with a neuropathic component. We successfully identified molecular targets of CBD that were relevant in the context of OA treatment with both beneficial and detrimental effects. Our findings were confirmed by in vivo and molecular studies. A key role of PPARγ in mediating the therapeutic potential of CBD was revealed, whereas upregulation of multiple transient receptor potential channels demasked CBD-induced heat hyperalgesia. Our findings pave the way for novel CBD-based therapy with improved therapeutic potential but also encourage the use of bioinformatic tools to predict the mechanism of action of CBD in different conditions. We have also created an accessible web tool for analogous analysis of CBD pharmacology in the context of any disease of interest and made it publicly available.

[1]  M. Bryk,et al.  Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review , 2021, Pharmacological Reports.

[2]  J. Mlost,et al.  Sodium Monoiodoacetate Dose-Dependent Changes in Matrix Metalloproteinases and Inflammatory Components as Prognostic Factors for the Progression of Osteoarthritis , 2021, Frontiers in Pharmacology.

[3]  M. Korostyński,et al.  CB2 agonism controls pain and subchondral bone degeneration induced by mono-iodoacetate: Implications GPCR functional bias and tolerance development. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  E. McDonagh,et al.  Open Targets Platform: supporting systematic drug–target identification and prioritisation , 2020, Nucleic Acids Res..

[5]  J. Mlost,et al.  Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action , 2020, International journal of molecular sciences.

[6]  Peter D. Currie,et al.  Integrated Value of Influence: An Integrative Method for the Identification of the Most Influential Nodes within Networks , 2020, Patterns.

[7]  Xiaochen Li,et al.  Excessive mechanical stress induces chondrocyte apoptosis through TRPV4 in an anterior cruciate ligament-transected rat osteoarthritis model. , 2019, Life sciences.

[8]  Y. Li,et al.  Models of osteoarthritis: the good, the bad and the promising , 2019, Osteoarthritis and cartilage.

[9]  S. O'Sullivan,et al.  A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans , 2018, Front. Pharmacol..

[10]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[11]  A. Dickenson,et al.  Modality selective roles of pro-nociceptive spinal 5-HT2A and 5-HT3 receptors in normal and neuropathic states , 2018, Neuropharmacology.

[12]  K. Gee,et al.  Positive allosteric modulators of nonbenzodiazepine &ggr;-aminobutyric acidA receptor subtypes for the treatment of chronic pain , 2018, Pain.

[13]  M. Alaverdashvili,et al.  Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors , 2018, British journal of pharmacology.

[14]  D. Hunter,et al.  Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis , 2018 .

[15]  J. Mlost,et al.  Molecular Understanding of the Activation of CB1 and Blockade of TRPV1 Receptors: Implications for Novel Treatment Strategies in Osteoarthritis , 2018, International journal of molecular sciences.

[16]  Julen Oyarzabal,et al.  Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors , 2017, Front. Pharmacol..

[17]  O. Krupkova,et al.  The role of transient receptor potential channels in joint diseases. , 2017, European cells & materials.

[18]  Irina Vetter,et al.  Methods Used to Evaluate Pain Behaviors in Rodents , 2017, Front. Mol. Neurosci..

[19]  I. McGregor,et al.  The direct actions of cannabidiol and 2‐arachidonoyl glycerol at GABAA receptors , 2017, Pharmacological research.

[20]  K. Mackie,et al.  Inflammatory and Neuropathic Nociception is Preserved in GPR55 Knockout Mice , 2017, Scientific Reports.

[21]  D. Selley,et al.  Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[22]  Farshid Guilak,et al.  Cartilage-Specific Knockout of the Mechanosensory Ion Channel TRPV4 Decreases Age-Related Osteoarthritis , 2016, Scientific Reports.

[23]  M. Nagarkatti,et al.  Critical Role of Mast Cells and Peroxisome Proliferator–Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo , 2015, The Journal of Immunology.

[24]  F. Guilak,et al.  TRPV4 as a therapeutic target for joint diseases , 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

[25]  Farshid Guilak,et al.  TRPV4-mediated mechanotransduction regulates the metabolic response of chondrocytes to dynamic loading , 2014, Proceedings of the National Academy of Sciences.

[26]  D. Barrett,et al.  Increased function of pronociceptive TRPV1 at the level of the joint in a rat model of osteoarthritis pain , 2013, Annals of the rheumatic diseases.

[27]  F. Piscitelli,et al.  Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics. , 2013, Pharmacological research.

[28]  M. Li,et al.  Selection of Suitable Reference Genes for Normalization of Quantitative Real-Time PCR in Cartilage Tissue Injury and Repair in Rabbits , 2012, International journal of molecular sciences.

[29]  Fei Yang,et al.  Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors , 2012, The Journal of experimental medicine.

[30]  D. Walsh,et al.  Differences in structural and pain phenotypes in the sodium monoiodoacetate and meniscal transection models of osteoarthritis , 2012, Osteoarthritis and cartilage.

[31]  A. Lichtman,et al.  Discovery of Prostamide F2α and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability , 2012, PloS one.

[32]  T. Bisogno,et al.  Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes , 2011, British journal of pharmacology.

[33]  B. Platt,et al.  Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour , 2011, Psychopharmacology.

[34]  W. Xiong,et al.  Psychotropic and nonpsychotropic cannabis derivatives inhibit human 5-HT3A receptors through a receptor desensitization-dependent mechanism , 2011, Neuroscience.

[35]  J. Kelly,et al.  Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide‐induced alterations in circulating cytokine levels in rats , 2008, Immunology.

[36]  I. Chessell,et al.  The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain , 2008, PAIN.

[37]  K. Mackie,et al.  GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current , 2008, Proceedings of the National Academy of Sciences.

[38]  M. Calaza,et al.  Reference genes for normalization of gene expression studies in human osteoarthritic articular cartilage , 2008, BMC Molecular Biology.

[39]  S. Hjorth,et al.  The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.

[40]  J. McDougall,et al.  Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat , 2005, Neuroscience Letters.

[41]  C. Woolf,et al.  Detection of cold pain, cold allodynia and cold hyperalgesia in freely behaving rats , 2005, Molecular pain.

[42]  Alyson Fox,et al.  Pain related behaviour in two models of osteoarthritis in the rat knee , 2004, Pain.

[43]  P. Gillet,et al.  Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. , 1997, Arthritis and rheumatism.

[44]  S. Barasi,et al.  The role of 5HT3 in nociceptive processing in the rat spinal cord: results from behavioural and electrophysiological studies , 1996, Neuroscience Letters.

[45]  T. Yaksh,et al.  Quantitative assessment of tactile allodynia in the rat paw , 1994, Journal of Neuroscience Methods.

[46]  S. O'Sullivan,et al.  Cannabinoid activation of peroxisome proliferator‐activated receptors: an update and review of the physiological relevance , 2013 .